Bruker Expands Drug Discovery Capabilities with Majority Investment in MIMETAS

Bruker Corporation (Nasdaq: BRKR) has revealed a majority investment in MIMETAS B.V., a developer of organ-on-a-chip platforms and human tissue models aimed at improving drug discovery and development. This acquisition will enhance Bruker’s post-genomic solutions in disease biology research and expand its reach into Microphysiological Systems (MPS), also known as New Approach Methodologies (NAMs), which are based on human physiology-relevant model systems.

MIMETAS specializes in scalable organ-on-a-chip solutions that enable the culturing and analysis of human-relevant tissues in a high-throughput plate format. The OrganoPlate® platform facilitates advanced disease modeling, drug testing, and safety assessments, showcasing features such as immune cell migration from a blood vessel, a vascularized liver model, a gut tubule, a colon organoid-derived tubule, and a vascularized lung model.

The company’s innovative platforms allow researchers to investigate disease mechanisms and responses to compounds in biologically relevant systems. The OrganoPlate® integrates with standard microtiter-plate formats and employs membrane-free microfluidic tissue cultures, which support imaging and automated handling, thereby enhancing research and development workflows. Bruker intends to merge these capabilities with its existing technologies in proteomics, metabolomics, NMR, preclinical imaging, and spatial biology.

“Human physiology-relevant tissue and disease models are becoming increasingly important for understanding disease biology and evaluating therapeutic candidates,” stated Frank H. Laukien, President and CEO of Bruker Corporation. He added, “The unique MIMETAS organ-on-a-chip platforms complement Bruker’s capabilities in multiomics, spatial biology, and preclinical imaging. We believe that humanized Microphysiological Systems, or NAMs, have a bright future, and will be increasingly adopted in drug discovery, development and preclinical testing.”

MIMETAS’s offerings include the OrganoPlate platform, OrganoReady® tissue and organoid products, as well as supporting instruments and contract research services. The two companies plan to create integrated product and service workflows that link these human model systems with Bruker’s technologies for molecular and cellular characterization.

A Senior Scientific Director at a global pharmaceutical company remarked, “The OrganoReady Colon Organoid Model combined with the OrganoTEER® system has become fully integrated into our toxicity-testing workflow. The platform fits seamlessly into our routine screening and supports consistent, reproducible data generation.”

“Joining Bruker creates opportunities to scale our platforms and make advanced human tissue models available to more researchers worldwide,” expressed Paul Vulto and Jos Joore, co-founders and co-CEOs of MIMETAS. They noted, “By combining our OrganoPlate and OrganoReady solutions with Bruker’s molecular and cellular characterization technologies, we aim to offer more integrated workflows for disease research, compound evaluation, and drug development.”

The collaboration between Bruker and MIMETAS is anticipated to connect advanced human tissue models with molecular, cellular, and spatial characterization, thereby aiding in evidence generation for disease research and drug-development decisions, as well as AI foundation models. Financial specifics of the deal remain undisclosed, but MIMETAS will retain its established brand and management.

About Bruker Corporation – Leader of the Post-Genomic Era (Nasdaq: BRKR) Bruker is enabling scientists and engineers to make breakthrough post-genomic discoveries and develop new applications that improve the quality of human life. Bruker’s high-performance scientific instruments and high-value analytical and diagnostic solutions enable scientists to explore life and materials at molecular, cellular, and microscopic levels. For more information, please visit www.bruker.com.

About MIMETAS: MIMETAS is a global leader in human organ-on-a-chip solutions for drug discovery and development. Through its proprietary OrganoPlate® platform, the company provides predictive human tissue and disease models that help pharmaceutical and biotechnology companies improve decision-making across the R&D pipeline. MIMETAS is committed to advancing human-centric research through innovative products, contract research services, and New Approach Methodologies.